Agilent Providing Tools to Stemina for Metabolomic Studies | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Agilent Technologies said yesterday that it is providing tools to Stemina Biomarker Discovery to accelerate its metabolomic research.

Agilent will provide Stemina with a 1290 Infinity UHPLC platform for the separation of stem cell metabolites, and a 6530 Q-TOF mass spec for the identification of metabolites. In addition, Agilent is providing Mass Profile Profession software for interpreting complex data generated from metabolomic research.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.